TRAP Intervention STudy: Early Versus Late Intervention for Twin Reversed Arterial Perfusion Sequence (TRAPIST)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT02621645 |
|
Recruitment Status :
Recruiting
First Posted : December 3, 2015
Last Update Posted : September 21, 2017
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Twin Reversal Arterial Perfusion Syndrome | Procedure: Early selective reduction of TRAP mass Procedure: Late selective reduction of TRAP mass Device: Ultrasound-guided intrafetal ablation using a 18 to 20 Gauge needle Device: Ultrasound-guided intrafetal ablation using a 17 to 20 Gauge needle Device: Laser coagulation of the cord or anastomising vessels through a 17 Gauge to 7 French trocar, with a 1-1,3 mm fetoscope and a 400 µm laser fiber | Phase 4 |
The investigators propose to conduct a multi-center open-label randomized controlled trial to assess if early intervention (12.0-14.0 weeks) (study group) improves the outcome of TRAP sequence as compared to late intervention (16.0-19.0 weeks) (control group). The investigators will randomly assign women diagnosed with TRAP sequence diagnosed between 11.6 and 13.6 weeks (1:1) to an early or late intervention group, using a web-based application (www.sealedenvelope.com) with a computer-generated list with random permuted blocks of sizes 2 or 4, stratified by gestational age at inclusion (11.6 -12.6 weeks versus 13.0-13.6 weeks). Analysis will be by intention-to-treat. Outcome will be adjudicated blinded to group allocation.
All interventions will be done under local anaesthesia and/or conscious sedation in sterile conditions by an experienced operator. They must be performed within 1 week after randomisation and at the latest at 14.0 weeks in the early group and 19.0 weeks in the late group. In the early group, only intrafetal coagulation will be used. Intrafetal ablation will be performed under ultrasound guidance using an 18-gauge (1.27 mm) to 20-gauge (0.91 mm) needle with a free-hand technique. The needle is introduced into the pelvis/abdomen of the TRAP mass close to the intra-abdominal portion of the feeding vessel, while avoiding puncture of the placenta and pump twin sac. The procedure is considered successful when there is complete cessation of reverse flow into the TRAP mass on intraoperative color-flow mapping.
In the late intervention/control group either intrafetal coagulation or fetoscopic laser coagulation will be performed of the cord and/or anastomosing vessels, unless the flow has stopped spontaneously or demise of the pump twin has occurred in the meantime. Intrafetal coagulation is done as described above by using a 17-gauge (1.47 mm) to 20-gauge needle. Alternatively, fetoscopic laser coagulation of the cord or anastomosing vessels can be performed through a 17-gauge to 7 French trocar with 1-1,3 mm fetoscope and 400 μm laser fiber. The rationale not to standardize the technique in the late intervention group is that several techniques have been reported for treatment after 16 weeks without any significant differences in outcome. Also, it is usual for the surgeon to adapt the technique to the requirements of each individual case, e.g. for a posterior placenta, the surgeon may prefer fetoscopic rather than intrafetal coagulation. Not restricting the technique to only 1 option will therefore more truly represent current practice and increase the generalizability of the trial's findings.
Patients will be discharged the same day or 1 day after the procedure. Management and follow-up will be similar for the study and the control or current practice group. A follow-up scan is usually performed 1 week after the intervention to check for fetal well-being and exclude anemia. A detailed ultrasound scan will be arranged in a fetal medicine center at 20 and 30 weeks to assess the heart and brain anatomy. Some centers may offer an MRI scan at around 30 weeks as part of the protocol for monochorionic twin pregnancies that underwent an intrauterine intervention. Antenatal, peripartum and postnatal care of the mother will be similar to that of a singleton pregnancy and at the discretion of the referring physician. Intrauterine intervention for TRAP sequence is not an indication for cesarean or elective preterm birth.
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 126 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | Early Versus Late Intervention for Twin Reversed Arterial Perfusion Sequence: an Open-label Randomized Controlled Trial: TRAPIST - TRAP Intervention STudy |
| Study Start Date : | May 2016 |
| Estimated Primary Completion Date : | June 2020 |
| Estimated Study Completion Date : | June 2022 |
| Arm | Intervention/treatment |
|---|---|
|
Experimental: Early intervention
Intervention between 12.0 and 14.0 weeks. Early selective reduction of TRAP mass.
|
Procedure: Early selective reduction of TRAP mass
Ultrasound-guided intrafetal ablation using an 18 Gauge to 20 Gauge needle Device: Ultrasound-guided intrafetal ablation using a 18 to 20 Gauge needle |
|
Active Comparator: Late intervention
Intervention between 16.0 and 19.0 weeks. Late selective reduction of TRAP mass. This is the standard timing of the intervention. One of two possible techniques for late reduction is chosen by the treating physician.
|
Procedure: Late selective reduction of TRAP mass
Ultrasound-guided intrafetal ablation using a 17 Gauge to 20 Gauge needle OR fetoscopic laser coagulation of the cord or anastomising vessels through a 17 Gauge to 7 French trocar, with a 1-1,3 mm fetoscope and a 400 µm laser fiber. The treating physician can decide which technique will be used for the selective reduction. Device: Ultrasound-guided intrafetal ablation using a 17 to 20 Gauge needle Device: Laser coagulation of the cord or anastomising vessels through a 17 Gauge to 7 French trocar, with a 1-1,3 mm fetoscope and a 400 µm laser fiber |
- Number of patients with neonatal survival and birth at or after 34.0 weeks of the pump twin [ Time Frame: 2 weeks after expected date of birth ]
- Number of patients with need for re-intervention [ Time Frame: 2 weeks after expected date of birth ]This means any kind of fetal intervention, such as repeated intrafetal coagulation, intra-uterine transfusion cord-occlusion...
- Number of patients with maternal morbidity [ Time Frame: 2 weeks after expected date of birth ]
Maternal morbidity is defined as presence of one or more of the following events:
- Need for transfusion for hemorrhage
- Abruption
- Chorioamnionitis as defined on pathology
- Sepsis
- Bowel perforation
- Other serious maternal morbidity requiring admission to ICU
- Number of patients with miscarriage [ Time Frame: 2 weeks after expected date of birth ]Number of patients with miscarriage before 24 weeks
- Number of patients with preterm prelabor rupture of membranes (PPROM) [ Time Frame: 2 weeks after expected date of birth ]Number of patients with rupture of membranes before onset of labor and before 37 weeks
- Number of patients with preterm birth prior to 28 weeks [ Time Frame: 2 weeks after expected date of birth ]Number of patients delivering before 28 weeks
- Number of patients with preterm birth prior to 32 weeks [ Time Frame: 2 weeks after expected date of birth ]Number of patients delivering before 32 weeks
- Number of patients with preterm birth prior to 37 weeks [ Time Frame: 2 weeks after expected date of birth ]Number of patients delivering before 37 weeks
- Time from randomization to delivery [ Time Frame: 2 weeks after expected date of birth ]Number of weeks between randomization and the time of delivery
- Time from randomization to PPROM [ Time Frame: 2 weeks after expected date of birth ]Number of weeks between randomization and rupture of membranes in patients with PPROM
- Birth weight in grams [ Time Frame: 42 days (28 days neonatal period+2 weeks postdates) after expected date of birth ]
- Number of patients with stillbirth [ Time Frame: 42 days (28 days neonatal period+2 weeks postdates) after expected date of birth ]Stillbirth refers to all patients with antepartum or intrapartum demise of the fetus
- Number of patients with neonatal death [ Time Frame: 42 days (28 days neonatal period+2 weeks postdates) after expected date of birth ]Demise of a live-born child within the first 28 days of life
- Number of patients with severe neonatal morbidity [ Time Frame: 42 days (28 days neonatal period+2 weeks postdates) after expected date of birth ]
Severe neonatal morbidity is defined as the presence of at least one of the following:
- chronic lung disease (defined as oxygen dependency at 36 weeks gestational age)
- patent ductus arteriosus needing medical therapy or surgical closure
- necrotizing enterocolitis stage 2 or higher
- retinopathy of prematurity stage 3 or higher
- ischemic limb injury
- amniotic band syndrome
- severe cerebral injury (includes at least one of the following: intraventricular hemorrhage grade 3 or higher, cystic periventricular leukomalacia grade 2 or higher, ventricular dilatation greater than the 97th centile, porencephalic or parenchymal cysts or other severe cerebral lesions).
- High volume vs low volume centers of neonatal survival and birth at or after 34.0 weeks of the pump twin and maternal morbidity parameters [ Time Frame: 2 weeks after expected date of birth ]
- Number of patients with intact survival rate [ Time Frame: 2 years after expected date of birth ]Intact survival rate defined as the number of surviving infants with normal development at two years corrected for prematurity as assessed by the ASQ® score for infant development (Ages & Stages Questionnaire). A score of more than 2 standard deviations below the mean score for term-born children will be considered abnormal.
- Number of patients with normal Bayley III score [ Time Frame: 2 years after expected date of birth ]Number of patients with normal Bayley III score at two years of age corrected for prematurity
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | Female |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- TRAP sequence in a monochorionic diamniotic twin pregnancy diagnosed between 11.6 and 13.6 weeks, as determined by the crown-rump length of the pump twin in spontaneous conceptions and by the date of insemination or embryonic age at replacement in pregnancies resulting from subfertility treatment
- Women aged 18 years or more, who are able to consent
- Anatomically normal pump twin
- Provide written informed consent to participate in this randomized controlled trial, forms being approved by the Ethical Committees
Exclusion Criteria:
- Contraindication for an intervention due to a severe maternal medical condition or threatening miscarriage
- Inaccessibility of the acardiac twin due to a retroverted uterus, severe maternal obesity, uterine fibroids, bowel or placental superposition
- A major anomaly in the pump twin, requiring surgery or leading to infant death or severe handicap
- Spontaneous arrest of the reverse flow and/or pump twin demise at diagnosis
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02621645
| Contact: Isabel Couck, MD | +32 16 342294 | isabel.couck@uzleuven.be | |
| Contact: Liesbeth Lewi, MD PhD | +32 16 342862 | liesbeth.lewi@uzleuven.be |
| United States, Texas | |
| Children's Memorial Hermann Hospital | Recruiting |
| Houston, Texas, United States | |
| Contact: Anthony Johnson | |
| Contact: Noemi Boring | |
| Austria | |
| Universitätsklinik für Frauenheilkunde und Geburtshilfe | Recruiting |
| Graz, Austria | |
| Contact: Philipp Klaritsch | |
| Belgium | |
| Universitaire Ziekenhuizen Leuven | Recruiting |
| Leuven, Belgium | |
| Contact: Liesbeth Lewi | |
| Canada | |
| Mount Sinai Hospital | Recruiting |
| Toronto, Canada | |
| Contact: Tim Van Mieghem | |
| Contact: Greg Ryan | |
| France | |
| Centre Médico-Chirurgical et Obstétrical | Recruiting |
| Schiltigheim, France | |
| Contact: Romain Favre | |
| Germany | |
| Universitätsklinikum Hamburg-Eppendorf | Recruiting |
| Hamburg, Germany | |
| Contact: Christian Bamberg | |
| Israel | |
| Sheba Medical Center | Recruiting |
| Tel Hashomer, Israel | |
| Contact: Yoav Yinon | |
| Italy | |
| Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico | Recruiting |
| Milan, Italy | |
| Contact: Nicola Persico | |
| Ospedale dei Bambini Vittore Buzzi | Recruiting |
| Milan, Italy | |
| Contact: Mariano Lanna | |
| Netherlands | |
| Leiden University Medical Center | Recruiting |
| Leiden, Netherlands | |
| Contact: Dick Oepkes | |
| Contact: Monique Haak | |
| Spain | |
| Hospital Universitari Vall d'Hebron | Recruiting |
| Barcelona, Spain | |
| Contact: Carlota Rodo | |
| United Kingdom | |
| Birmingham Women's Hospital | Recruiting |
| Birmingham, United Kingdom | |
| Contact: Mark Kilby | |
| King's College | Recruiting |
| London, United Kingdom | |
| Contact: Sarah Bower | |
| St. George's Hospital, University of London (UK sponsor) | Recruiting |
| London, United Kingdom | |
| Contact: Asma Khalil | |
| Contact: Sarah Davies | |
| Study Chair: | Liesbeth Lewi, MD PhD | UZ Leuven |
Publications:
| Responsible Party: | Universitaire Ziekenhuizen Leuven |
| ClinicalTrials.gov Identifier: | NCT02621645 History of Changes |
| Other Study ID Numbers: |
S58224 |
| First Posted: | December 3, 2015 Key Record Dates |
| Last Update Posted: | September 21, 2017 |
| Last Verified: | January 2017 |
|
monochorionic TRAP acardiac twin |